Takeda considering selling its Russian manufacturing plant

Japanese pharmaceutical giant Takeda (TYO: 4502) is considering selling its Russian plant that produces, Ninlaro (ixazomib), a treatment for patients with multiple myeloma as well as other drugs, according to some local market analysts and Russian media, The Pharma Letters local correspondent reports.

According to the Russian Kommersant business paper, so far, a number of Russian companies have expressed an interest in the acquisition of the company’s Yaroslavl enterprise, there have been no specific negotiations to date.

According to SPARK-Interfax, in 2021, the revenue of Takeda Pharmaceutical, the Russian legal entity of the company, amounted to 21.9 billion roubles, which is up 22% year-on-year.